Author | Ikenna Madueke, MD, PhD

Articles

Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?

June 19, 2019

In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.